Skip to content

CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved.

Stock of the day: ResMed

Despite the challenges posed by GLP-1 weight loss drugs, ResMed's Q2 report shows a robust 9% increase in revenue and strong earnings per share, signaling a promising future and making it a compelling buy for investors.

Video poster image

[AI generated]

This video was created on 2 August for IG audiences by ausbiz.

Stock of the day: ResMed (ASX:RMD)

Impressive revenue growth and earnings defy market challenges

In the second quarter, ResMed demonstrated remarkable financial resilience, posting a 9% increase in revenue, reaching US$1.22 billion, and earnings of US$1.98 per share. This performance is particularly noteworthy given the potential disruptions from the emerging market of GLP-1 weight loss drugs, which instead have been turned into opportunities, enhancing both prescription volumes and patient retention in associated therapies.

During a recent press conference, Reserve Bank Australia Governor Mick Farrell addressed the so-called "elephant in the room"—the impact of GLP-1 drugs. He highlighted an ongoing study tracking over 800,000 patients prescribed GLP-1 drugs who subsequently began positive airway pressure therapy. Results show increased patient engagement over time, suggesting a synergistic effect rather than a detrimental one.

What the future holds

As ResMed enters a new financial year, the outlook is positive. With a forward earnings trading multiple around 25-26 times, the valuation remains attractive given the company's history and operational stability. While potential volatility from external market factors like Eli Lilly's upcoming results could affect the stock, the long-term prospects for ResMed are encouraging.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.

Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

Explore the markets with our free course

Discover the range of markets you can spread bet on - and learn how they work - with IG Academy's online course.

Turn knowledge into success

Practice makes perfect. Take what you’ve learned in this index strategy article, and try it out risk-free in your demo account.

Ready to trade indices?

Put the lessons in this article to use in a live account. Upgrading is quick and simple.

  • Get fixed spreads from 1 point on FTSE 100 and Germany 40
  • Protect your capital with risk management tools
  • Trade more 24-hour markets than any other provider – 26 in total

Inspired to trade?

Put the knowledge you’ve gained from this article into practice. Log in to your account now.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Tuesday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.